![logo](/logos/EVLO.webp)
Evelo Biosciences, Inc.
NASDAQ:EVLO
0 (USD) • At close January 6, 2025
Overzicht | Financiële gegevens
Bedrijfsnaam | Evelo Biosciences, Inc. |
Symbool | EVLO |
Munteenheid | USD |
Prijs | 0.001 |
Beurswaarde | 9,491 |
Dividendpercentage | 0% |
52-weken bereik | 0 - 0.075 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Balkrishan Gill Ph.D. |
Website | https://www.evelobio.com |
An error occurred while fetching data.
Over Evelo Biosciences, Inc.
Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in Phase 2 clinical trial for the treatment of psoriasis and atopic dermatitis, as well as
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)